Use of strain of lactobacillus plantarum, metabolite thereof, or composition containing same for repairing or preventing retinal injury

Abstract

The invention provides application of a lactobacillus plantarum PL-02 strain, a metabolite of the lactobacillus plantarum PL-02 strain or a composition containing the lactobacillus plantarum PL-02 strain, the lactobacillus plantarum PL-02 strain is used for preparing medicine, food or nourishment for repairing or preventing retinal injury, the lactobacillus plantarum PL-02 strain is deposited in the China General Microbiological Culture Collection Center, and the depositing number is CGMCC20485.

Description

Technical Field

[0001] The present invention relates to the use of Lactobacillus plantarum strains or metabolites thereof, and particularly to the use of Lactobacillus plantarum strains, metabolites thereof, or compositions containing the same for repairing or preventing retinal damage. Background Art

[0002] Sunlight, LED lamps, and 3C electronic product screens are all common sources of blue light. The wavelength of blue light is between 380 and 500nm, and it has high energy, which belongs to "high-energy visible light (HEVlight)". Blue light is harmful to the eyes, so it is also called "harmful blue light". Studies have shown that blue light can cause visual fatigue, premature eye aging, and age-related macular degeneration. Long-term exposure to blue light will increase cellular oxidative stress and cause the death of retinal ganglion cells.

[0003] Macular degeneration, also known as age-related macular degeneration (AMD), is the third leading cause of blindness in the world. The main cause is the aging of the retina, which leads to decreased vision, and in severe cases may lead to blindness. Oxidative damage caused by light and the reduction of macular pigment can both cause macular degeneration. In the light sensitivity test, the subjects are more sensitive to short-wavelength light than other wavelengths. Short-wavelength light has greater energy, so it is more harmful to the eyes. Studies have shown that macular pigment has the lowest sensitivity to light waves with a wavelength of 460nm. When the light enters the photoreceptor layer of the eye, the macular pigment can absorb it to reduce eye discomfort. With the advancement of technology, modern people spend more time using electronic products and looking at the screen. Although there are many different anti-blue light products and health supplements on the market, they still cannot effectively block the damage of blue light.

[0004] Probiotics are live microorganisms that are beneficial to the health of the host. Common bacteria include Lactobacillus spp. and Bifidobacterium spp., which can improve intestinal flora and flora imbalance, adjust intestinal discomfort, improve constipation, protect the liver and kidneys, anti-aging and regulate immunity.

[0005] Currently, attempts are being made to use lactic acid bacteria to improve eye-related symptoms. For example, Lactobacillus paracasei KW3110 can effectively improve blue light-induced eye fatigue and related diseases. However, the biological activity of probiotics is strain-specific, and not all strains of the same species have the same activity and efficacy. In other words, different strains of the same species may have different characteristics and efficacy.

[0006] Therefore, developing medicines, foods, or nutritional products that can improve eye-related symptoms by discovering new active effects of lactic acid bacteria strains is indeed one of the issues that people in the relevant technical fields are actively trying to solve. Summary of the invention

[0007] It is found herein that Lactobacillus plantarum PL-02 strain or its metabolites can reduce the damage caused by blue light irradiation to human retinal epithelial cells. It is further found herein that the mixture of this strain and other strains in a specific ratio can synergistically compensate for the damage caused by blue light irradiation to human retinal epithelial cells. Therefore, Lactobacillus plantarum PL-02 strain, its metabolites, and compositions containing the same can improve eye discomfort symptoms and enhance eye clarity, and have eye protection effects.

[0008] Therefore, the present invention proposes a use of a Lactobacillus plantarum PL-02 strain or its metabolites, which is used to prepare medicines, foods, or nutritional products for repairing or preventing retinal damage. The Lactobacillus plantarum PL-02 strain is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC20485.

[0009] Preferably, the retinal damage is retinal damage caused by blue light irradiation.

[0010] Preferably, the retinal damage comprises macular degeneration, retinitis pigmentosa, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, hypertensive retinopathy, retinopathy of prematurity, radiation retinopathy, or heliotropic retinopathy.

[0011] Preferably, the medicine or nutrition product is for topical ocular, intraocular, or oral administration to a subject in need of repair or prevention, and the food product is for oral administration to a subject in need of repair or prevention.

[0012] Preferably, the medicine, food, or nutritional product is used to repair retinal epithelial cell damage caused by blue light irradiation.

[0013] In addition, the present invention further provides a use of a strain composition, which is used for preparing medicine, food, or nutrition for repairing or preventing retinal damage. The strain composition includes: Lactobacillus plantarum PL-02 strain, Lactobacillus salivarius subsp.salicinius AP-32 strain, Lactobacillus plantarum LPL28 strain, Bifidobacterium longum subsp.infantis BLI-02 strain, and Lactobacillus acidophilus TYCA06 strain; Lactobacillus plantarum PL-02 strain is deposited in the China Center for General Microbiological Culture Collection with a deposit number of CGMCC20485; Lactobacillus salivarius AP-32 strain is deposited in the China Center for Type Culture Collection with a deposit number of CCTCC M2011127; Lactobacillus plantarum LPL28 strain is deposited in China Center for General Microbiological Culture Collection with the deposit number CGMCC17954; Bifidobacterium longum infantis subspecies BLI-02 strain is deposited in China Center for General Microbiological Culture Collection with the deposit number CGMCC15212; Lactobacillus acidophilus TYCA06 strain is deposited in China Center for General Microbiological Culture Collection with the deposit number CGMCC15210; based on the total strain amount of the strain composition, Lactobacillus plantarum PL-02 strain accounts for 50 to 70 cfu, Lactobacillus salivarius AP-32 strain accounts for 7.5 to 12.5 cfu, Lactobacillus plantarum LPL28 strain accounts for 7.5 to 12.5 cfu, Bifidobacterium longum infantis subspecies BLI-02 strain accounts for 7.5 to 12.5 cfu, and Lactobacillus acidophilus TYCA06 strain accounts for 7.5 to 12.5 cfu%.

[0014] Preferably, the retinal damage is retinal damage caused by blue light irradiation.

[0015] Preferably, the retinal damage comprises macular degeneration, retinitis pigmentosa, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, hypertensive retinopathy, retinopathy of prematurity, radiation retinopathy, or heliotropic retinopathy.

[0016] Preferably, the medicine or nutrition product is for topical ocular, intraocular, or oral administration to a subject in need of repair or prevention, and the food product is for oral administration to a subject in need of repair or prevention.

[0017] Preferably, the medicine, food, or nutritional product is used to repair retinal epithelial cell damage caused by blue light irradiation.

[0018] Furthermore, the present invention provides a use of a strain composition, which is used for preparing medicine, food, or nutrition for repairing or preventing retinal damage. The strain composition includes: Lactobacillus plantarum PL-02 strain, Lactobacillus salivarius AP-32 strain, Lactobacillus plantarum LPL28 strain, Bifidobacterium longum infantis subspecies BLI-02 strain, and Lactobacillus acidophilus TYCA06 strain; Lactobacillus plantarum PL-02 strain is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC20485; Lactobacillus salivarius AP-32 strain is deposited in the China Center for Type Culture Collection with a deposit number of CCTCC M2011127; Lactobacillus plantarum LPL28 strain was deposited in the China Center for General Microbiological Culture Collection with the deposit number CGMCC17954; Bifidobacterium longum infantis subspecies BLI-02 strain was deposited in the China Center for General Microbiological Culture Collection with the deposit number CGMCC15212; Lactobacillus acidophilus TYCA06 strain was deposited in the China Center for General Microbiological Culture Collection with the deposit number CGMCC15210; the cfu strain quantity ratio between Lactobacillus plantarum PL-02 strain, Lactobacillus salivarius AP-32 strain, Lactobacillus plantarum LPL28 strain, Bifidobacterium longum infantis subspecies BLI-02 strain, and Lactobacillus acidophilus TYCA06 strain is (15 to 35): 3.75: 3.75: 3.75: 3.75.

[0019] Preferably, the retinal damage is retinal damage caused by blue light irradiation.

[0020] Preferably, the retinal damage comprises macular degeneration, retinitis pigmentosa, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, hypertensive retinopathy, retinopathy of prematurity, radiation retinopathy, or heliotropic retinopathy.

[0021] Preferably, the medicine or nutrition product is for topical ocular, intraocular, or oral administration to a subject in need of repair or prevention, and the food product is for oral administration to a subject in need of repair or prevention.

[0022] Preferably, the medicine, food, or nutritional product is used to repair retinal epithelial cell damage caused by blue light irradiation. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The figure is a histogram comparing the degree of repair of different strains on the damage caused by blue light irradiation to human retinal epithelial cells ARPE-19; compared with the control group, ***P<0.001; compared with the blue light group,

[0024] ###P<0.001, #P<0.05;

[0025] Figure 2 The figure is a histogram, comparing the degree of repair of damage caused by blue light irradiation to human retinal epithelial cells ARPE-19 by different strain combinations; compared with the control group, ***P<0.001; compared with the blue light group, ###P<0.001, ##P<0.01, #P<0.05. DETAILED DESCRIPTION

[0026] In order to make the above and / or other purposes, effects, and features of the present invention more clearly understood, preferred embodiments are specifically described below in detail as follows:

[0027] The strains mentioned in this article are deposited in the China Center for the Preservation of General Microbiological Cultures, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, or the China Center for Type Culture Collection, Wuhan University, Wuhan, China. Detailed deposit information is shown in Table 1.

[0028] Table 1. Deposit information

[0029]

[0030] The strains mentioned in this article were identified by 16S rDNA sequence analysis and API bacterial identification system analysis. The morphological and general characteristics are shown in Table 2.

[0031] Table 2. Morphology and general properties

[0032]

[0033]

[0034] The first embodiment of the present invention is based on the discovery that the Lactobacillus plantarum PL-02 strain and its metabolites can compensate for the damage caused by blue light irradiation to human retinal epithelial cells ARPE-19. Accordingly, the first embodiment of the present invention proposes a use of the Lactobacillus plantarum PL-02 strain or its metabolites, which is used to prepare medicines, foods, or nutritional products for repairing or preventing retinal damage. In one embodiment, the Lactobacillus plantarum PL-02 strain is an active strain or a deactivated strain. In one embodiment, the retinal damage is retinal damage caused by blue light irradiation. In one embodiment, the retinal damage includes macular degeneration, retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, hypertensive retinopathy, retinopathy of prematurity, radiation retinopathy, or heliotropic retinopathy.

[0035] In one embodiment, the medicine or nutritional supplement is administered topically, intraocularly, or orally to an individual in need of repair or prevention, and the food is administered orally to an individual in need of repair or prevention, thereby achieving a repair or prevention effect. In one embodiment, the medicine, food, or nutritional supplement can repair retinal epithelial cell damage caused by blue light irradiation, thereby achieving a repair or prevention effect. In one embodiment, the medicine, food, or nutritional supplement is administered at a dose of 10 g / kg body weight per day. 6 Up to 10 10 CFU of the strain is administered to an individual to achieve a repair or preventive effect; preferably, the medicine, food, or nutritional product is administered at a dose of 8.3 x 10 per kg of body weight per day. 7 Up to 3.4x10 8 The amount of the strain in CFU is administered to a subject.

[0036] In one embodiment, the medicine, food, or nutritional product further comprises a physiologically acceptable excipient, diluent, or carrier.

[0037] In the context of food or nutritional products, the physiologically acceptable excipient, diluent or carrier is an edible excipient, diluent or carrier, examples of which are fluid dairy products (such as milk or condensed milk), fermented dairy products (such as yogurt), milk powder, ice cream, cheese, cottage cheese, soy milk, fermented soy milk, vegetable and fruit juices, fruit juices, sports drinks, jellies, biscuits, energy bars, health foods, animal feed, or dietary supplements, but are not limited thereto.

[0038] In the case of medicine or nutrition, the physiologically acceptable excipient, diluent or carrier is a pharmacologically acceptable excipient, diluent or carrier, examples of which are solvents, buffers, emulsifiers, suspending agents, decomposers, disintegrants, dispersants, binders, stabilizers, chelating agents, gelling agents, wetting agents, lubricants, absorption delay agents, or liposomes, but not limited thereto. The medicine or nutrition is in a dosage form for topical eye, intraocular, or oral administration. Examples of oral administration dosage forms are powders, lozenges, tablets, buccal tablets, pills, capsules, solutions, suspensions, emulsions, syrups, elixirs, slurries, or drops, but not limited thereto; examples of topical eye administration dosage forms are drops, emulsions, gels, ointments, creams, sprays, or suspensions, but not limited thereto; examples of intraocular administration dosage forms are drops, emulsions, gels, ointments, creams, sprays, or suspensions, but not limited thereto.

[0039] The second embodiment of the present invention is based on the discovery that the mixture of Lactobacillus plantarum PL-02 strain and other strains can synergistically compensate for the damage caused by blue light irradiation to human retinal epithelial cells ARPE-19. Accordingly, the second embodiment of the present invention proposes a use of a strain composition, which is used for preparing medicine, food, or nutrition for repairing or preventing retinal damage. The strain composition includes: Lactobacillus plantarum PL-02 strain, Lactobacillus salivarius AP-32 strain, Lactobacillus plantarum LPL28 strain, Bifidobacterium longum infantis subsp. BLI-02 strain, and Lactobacillus acidophilus TYCA06 strain; wherein the following conditions are met: (1) based on the total strain amount of the strain composition, Lactobacillus plantarum PL-02 strain accounts for 50 to 70 cfu%, and Lactobacillus salivarius AP-32 strain accounts for 7.5 to 12. 5cfu%, Lactobacillus plantarum LPL28 strain accounts for 7.5 to 12.5cfu, Bifidobacterium longum infantis subspecies BLI-02 strain accounts for 7.5 to 12.5cfu, and Lactobacillus acidophilus TYCA06 strain accounts for 7.5 to 12.5cfu%; or (2) the cfu strain quantity ratio between Lactobacillus plantarum PL-02 strain, Lactobacillus salivarius AP-32 strain, Lactobacillus plantarum LPL28 strain, Bifidobacterium longum infantis subspecies BLI-02 strain, and Lactobacillus acidophilus TYCA06 strain is (15 to 35): 3.75: 3.75: 3.75: 3.75.

[0040] In one embodiment, based on the total strain amount of the strain composition, Lactobacillus plantarum PL-02 accounts for 50 cfu, Lactobacillus salivarius AP-32 accounts for 12.5 cfu, Lactobacillus plantarum LPL28 accounts for 12.5 cfu, Bifidobacterium longum subsp. infantis BLI-02 accounts for 12.5 cfu, and Lactobacillus acidophilus TYCA06 accounts for 12.5 cfu.

[0041] In one embodiment, the cfu strain quantity ratio among Lactobacillus plantarum PL-02, Lactobacillus salivarius AP-32, Lactobacillus plantarum LPL28, Bifidobacterium longum subsp. infantis BLI-02, and Lactobacillus acidophilus TYCA06 is 15:3.75:3.75:3.75:3.75.

[0042] In one embodiment, Lactobacillus plantarum PL-02, Lactobacillus salivarius AP-32, Lactobacillus plantarum LPL28, Bifidobacterium longum subsp. infantis BLI-02, and Lactobacillus acidophilus TYCA06 are individually active strains or inactivated strains. In one embodiment, retinal damage is retinal damage caused by blue light irradiation. In one embodiment, retinal damage includes macular degeneration, retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, hypertensive retinopathy, retinopathy of prematurity, radiation retinopathy, or heliotropic retinopathy.

[0043] In one embodiment, the medicine or nutritional supplement is administered topically, intraocularly, or orally to an individual in need of repair or prevention, and the food is administered orally to an individual in need of repair or prevention, thereby achieving a repair or prevention effect. In one embodiment, the medicine, food, or nutritional supplement can repair retinal epithelial cell damage caused by blue light irradiation, thereby achieving a repair or prevention effect. In one embodiment, the medicine, food, or nutritional supplement is administered at a dose of 10 g / kg body weight per day. 6 Up to 10 10 The total amount of CFU of the strain is administered to the individual to achieve a repair or preventive effect; preferably, the medicine, food, or nutritional product is 8.3x10 per kg of body weight per day. 7 Up to 3.4x10 8 The total amount of strain CFU is administered to a subject.

[0044] In one embodiment, the medicine, food, or nutritional product further comprises a physiologically acceptable excipient, diluent, or carrier.

[0045] In the context of food or nutritional products, the physiologically acceptable excipient, diluent or carrier is an edible excipient, diluent or carrier, examples of which are fluid dairy products (such as milk or condensed milk), fermented dairy products (such as yogurt), milk powder, ice cream, cheese, cottage cheese, soy milk, fermented soy milk, vegetable and fruit juices, fruit juices, sports drinks, jellies, biscuits, energy bars, health foods, animal feed, or dietary supplements, but are not limited thereto.

[0046] In the case of medicine or nutrition, the physiologically acceptable excipient, diluent or carrier is a pharmacologically acceptable excipient, diluent or carrier, examples of which are solvents, buffers, emulsifiers, suspending agents, decomposers, disintegrants, dispersants, binders, stabilizers, chelating agents, gelling agents, wetting agents, lubricants, absorption delay agents, or liposomes, but not limited thereto. The medicine or nutrition is in a dosage form for topical eye, intraocular, or oral administration. Examples of oral administration dosage forms are powders, lozenges, tablets, buccal tablets, pills, capsules, solutions, suspensions, emulsions, syrups, elixirs, slurries, or drops, but not limited thereto; examples of topical eye administration dosage forms are drops, emulsions, gels, ointments, creams, sprays, or suspensions, but not limited thereto; examples of intraocular administration dosage forms are drops, emulsions, gels, ointments, creams, sprays, or suspensions, but not limited thereto.

[0047] The present invention is illustrated by the following embodiments:

[0048] <Example 1: Strain cultivation>

[0049] The strains used include: Lactobacillus plantarum PL-02, Lactobacillus salivarius AP-32, Lactobacillus plantarum LPL28, Bifidobacterium longum subsp. infantis BLI-02, Lactobacillus acidophilus TYCA06, and Lactobacillus paracasei KW3110.

[0050] The strain was inoculated into MRS broth containing 0.05 wt% cysteine ​​and cultured in an incubator (37°C, 5% CO2) for 24 hours to activate the strain. Then, the strain concentration of the obtained bacterial solution was adjusted to 1x10 9 CFU / mL.

[0051] <Example 2: In vitro testing of a single bacterial strain to mitigate cell damage caused by blue light>

[0052] MTT assay was used to detect cell viability. To simulate oral probiotics, the single strains were co-cultured with human colon cells Caco-2 for 6 hours, with the same strain amount for all single strains. The culture was then centrifuged at 4,000 rpm for 10 minutes to obtain the supernatant. The supernatant was co-cultured with human retinal epithelial cells ARPE-19 overnight, during which time it was irradiated with blue light. After removing the culture medium and washing the cells with PBS, the MTT assay was performed to determine the cell viability. Specifically, MTT was added

[0053] After adding 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to each well, the cells were allowed to react for 1 to 4 hours in an incubator at 37°C and 5% CO2. After removing MTT, the absorbance at a wavelength of 570nm was measured using an ELISA reader. Finally, the average absorbance of the experimental group was divided by the average absorbance of the control group to obtain the cell survival rate of the experimental group.

[0054] Please refer to Figure 1 , the survival rate of ARPE-19 cells can be reduced to 64% after blue light irradiation. After comparing the effects of different single strains on cell survival rate after blue light irradiation, it can be seen that Lactobacillus plantarum PL-02 strain can significantly increase cell survival rate to 79%, and Lactobacillus plantarum LPL28 strain can increase cell survival rate to 70%, indicating that Lactobacillus plantarum is strain-specific in mitigating retinal epithelial cell damage caused by blue light. Common eye protection ingredients vitamin A and lutein can increase cell survival rate to 62% and 64% respectively, and the commercially available eye protection strain Lactobacillus paracasei KW3110 strain can increase cell survival rate to 67%.

[0055] <Example 3: In vitro testing of combined strains to mitigate cell damage caused by blue light>

[0056] The percentage of strain amounts of different strains in the combined strain group is shown in Table 3.

[0057] Table 3. Strain quantity percentage

[0058]

[0059]

[0060] Cell viability was measured using MTT assay. To simulate oral administration of probiotics, each group was first co-cultured with human colonic Caco-2 cells for 6 hours. The total strain amount of all single-strain groups and all combined strain groups was the same. The culture was then centrifuged at 4,000 rpm for 10 minutes to obtain the supernatant. The supernatant was co-cultured with human retinal epithelial cells ARPE-19 overnight and irradiated with blue light. After removing the culture medium and washing the cells with PBS, the MTT assay was performed to determine the cell viability. Specifically, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) was added to each well and allowed to react with the cells in an incubator at 37°C and 5% CO2 for 1 to 4 hours. After removing MTT, the absorbance at a wavelength of 570 nm was measured using an ELISA reader. Finally, the average absorbance of the experimental group was divided by the average absorbance of the control group to obtain the cell viability of the experimental group.

[0061] Please refer to Figure 2 , the survival rate of ARPE-19 cells can be reduced to 64% after blue light irradiation. After comparing the effects of different single strains on cell survival after blue light irradiation, it can be seen that Lactobacillus plantarum PL-02 strain can increase cell survival rate to 79%, Bifidobacterium longum infantis subspecies BLI-02 strain can increase cell survival rate to 72%, Lactobacillus acidophilus TYCA06 strain can reduce cell survival rate to 62%, Lactobacillus salivarius AP-32 strain can reduce cell survival rate to 63%, and Lactobacillus plantarum LPL28 strain can increase cell survival rate to 70%. After comparing the effects of different combined strains on cell survival rate after blue light irradiation, it can be seen that combined strain groups 1 to 6 can increase cell survival rate to 73%, 80%, 82%, 72%, 70%, and 68%, respectively. In particular, the cell survival rates of combined strain groups 2 and 3 are greater than those of all single strain groups, indicating that the strain quantity ratio defined by combined strain groups 2 and 3 has a synergistic improvement in cell survival rate after blue light irradiation.

[0062] The cell repair rate after blue light irradiation in this experimental group is defined as:

[0063]

[0064] The cell repair rates after blue light irradiation for all single strain groups and all combined strain groups are shown in Table 4.

[0065] Table 4. Cell repair rate

[0066]

[0067] After comparing the effects of different combined strains on the cell repair rate after blue light irradiation, it can be seen that the cell repair rates of combined strain groups 2 and 3 are greater than those of all single strain groups, indicating that the strain quantity ratio defined by combined strain groups 2 and 3 has a synergistic improvement on cell repair after blue light irradiation.

[0068] However, what is described above is only a preferred embodiment of the present invention, but it cannot be used to limit the scope of implementation of the present invention; therefore, all simple equivalent changes and modifications made according to the scope of protection of the patent application of the present invention and the contents of the invention specification are still within the scope of protection of the patent of the present invention.

[0069]

Biological material storage

[0070] CNChina China General Microbiological Culture Collection Management Center 2020 / 08 / 06CGMCC20485;

[0071] CN China Center for Type Culture Collection 2011 / 04 / 10CCTCC M2011127;

[0072] CNChina China General Microbiological Culture Collection Administration Center 2019 / 06 / 18CGMCC17954;

[0073] CNChina China General Microbiological Culture Collection Center 2018 / 01 / 15CGMCC15212;

[0074] CNChina China General Microbiological Culture Collection Center2018 / 01 / 15CGMCC15210.

Claims

1. A use of a Lactobacillus plantarum PL-02 strain or a metabolite thereof, characterized in that: Used for preparing medicine, food, or nutrition for repairing or preventing retinal damage. The plant lactobacillus PL-02 strain is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC20485.

2. The use according to claim 1, characterized in that The retinal damage is caused by blue light exposure.

3. The use according to claim 1, characterized in that The retinal damage includes macular degeneration, retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, hypertensive retinopathy, retinopathy of prematurity, radiation retinopathy, or heliotropic retinopathy.

4. The use according to claim 1, characterized in that The medicine or nutrition product is used for topical eye, intraocular, or oral administration to an individual with repair or prevention needs, and the food product is used for oral administration to an individual with repair or prevention needs.

5. The use according to claim 1, characterized in that: The medicine, food or nutrition product is used to repair retinal epithelial cell damage caused by blue light irradiation.

6. A use of a strain composition, characterized in that: The invention is used for preparing medicine, food or nutrition for repairing or preventing retinal damage. The strain composition comprises: Lactobacillus plantarum PL-02 strain, Lactobacillus salivarius AP-32 strain, Lactobacillus plantarum LPL28 strain, Bifidobacterium longum infantis subspecies BLI-02 strain and Lactobacillus acidophilus TYCA06 strain; the Lactobacillus plantarum PL-02 strain is deposited in the China Center for Collection of General Microbiological Cultures with a deposit number of CGMCC20485; the Lactobacillus salivarius AP-32 strain is deposited in the China Center for Type Culture Collection with a deposit number of CCTCC M2011127; the Lactobacillus plantarum LPL28 strain is deposited in the China General Microorganism Culture Collection Center with a deposit number of CGMCC17954; the Bifidobacterium longum infantis subspecies BLI-02 strain is deposited in the China General Microorganism Culture Collection Center with a deposit number of CGMCC15212; the Lactobacillus acidophilus TYCA06 strain is deposited in the China General Microorganism Culture Collection Center with a deposit number of CGMCC15210; based on the total strain amount of the strain composition, the Lactobacillus plantarum PL-02 strain accounts for 50 to 70 cfu%, the Lactobacillus salivarius AP-32 strain accounts for 7.5 to 12.5 cfu%, the Lactobacillus plantarum LPL28 strain accounts for 7.5 to 12.5 cfu%, the Bifidobacterium longum infantis subspecies BLI-02 strain accounts for 7.5 to 12.5 cfu%, and the Lactobacillus acidophilus TYCA06 strain accounts for 7.5 to 12.5 cfu%.

7. A use of a strain composition, characterized in that: The invention is used for preparing medicine, food or nutrition for repairing or preventing retinal damage. The strain composition comprises: Lactobacillus plantarum PL-02 strain, Lactobacillus salivarius AP-32 strain, Lactobacillus plantarum LPL28 strain, Bifidobacterium longum infantis subspecies BLI-02 strain and Lactobacillus acidophilus TYCA06 strain; the Lactobacillus plantarum PL-02 strain is deposited in the China Center for Collection of General Microbiological Cultures with a deposit number of CGMCC20485; the Lactobacillus salivarius AP-32 strain is deposited in the China Center for Type Culture Collection with a deposit number of CCTCC M2011127; the Lactobacillus plantarum LPL28 strain is deposited in the China Center for General Microbiological Culture Collection with a deposit number of CGMCC17954; the Bifidobacterium longum infantis subspecies BLI-02 strain is deposited in the China Center for General Microbiological Culture Collection with a deposit number of CGMCC15212; the Lactobacillus acidophilus TYCA06 strain is deposited in the China Center for General Microbiological Culture Collection with a deposit number of CGMCC15210; the cfu strain quantity ratio between the Lactobacillus plantarum PL-02 strain, the Lactobacillus salivarius AP-32 strain, the Lactobacillus plantarum LPL28 strain, the Bifidobacterium longum infantis subspecies BLI-02 strain, and the Lactobacillus acidophilus TYCA06 strain is (15 to 35): 3.75: 3.75: 3.75: 3.

75.

8. The use according to claim 6 or 7, characterized in that The retinal damage is caused by blue light exposure.

9. The use according to claim 6 or 7, characterized in that The retinal damage includes macular degeneration, retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, hypertensive retinopathy, retinopathy of prematurity, radiation retinopathy, or heliotropic retinopathy.

10. The use according to claim 6 or 7, characterized in that: The medicine or nutrition product is used for topical eye, intraocular, or oral administration to an individual with repair or prevention needs, and the food product is used for oral administration to an individual with repair or prevention needs.

11. The use according to claim 6 or 7, characterized in that: The medicine, food or nutrition product is used to repair retinal epithelial cell damage caused by blue light irradiation.

Images